AbCellera Biologics Inc. ABCL Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount.
The official record: AbCellera Biologics Inc.’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s equity securities without readily determinable fair value, upward price adjustment, annual amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s equity securities without readily determinable fair value, upward price adjustment, annual amount?
- AbCellera Biologics Inc. (ABCL) reported equity securities without readily determinable fair value, upward price adjustment, annual amount of $50K in Q4 2025.
- How has AbCellera Biologics Inc.'s equity securities without readily determinable fair value, upward price adjustment, annual amount changed year-over-year?
- AbCellera Biologics Inc.'s equity securities without readily determinable fair value, upward price adjustment, annual amount decreased by 98.8% year-over-year, from $4.15M to $50K.
- What is the long-term trend for AbCellera Biologics Inc.'s equity securities without readily determinable fair value, upward price adjustment, annual amount?
- Over 2 years (2023 to 2025), AbCellera Biologics Inc.'s equity securities without readily determinable fair value, upward price adjustment, annual amount has grown at a -66.7% compound annual growth rate (CAGR), from $1.8M to $200K.
- What does equity securities without readily determinable fair value, upward price adjustment, annual amount mean?
- Reflects upward adjustments in the carrying value of private equity investments or non-marketable securities. It indicates the appreciation in value of strategic investments where a public market price is not available.